🔗 Share this article Individuals Coming Off Weight-Loss Medications Put On Pounds at a Quadrupled Rate Than People Using Diet and Exercise Obesity treatment involves ongoing approaches. A recent study suggests that individuals who come off new weight-loss injections like Wegovy and Mounjaro can put back on shed pounds much more quickly than those who end conventional lifestyle regimens. Research printed in a leading medical journal points out that while overweight individuals can lose about a fifth of their body weight while using the jabs, the weight comes back at an average rate of nearly a kilo each month once they quit. "People purchasing these treatments must be informed of the danger of fast rebound weight gain when the treatment ends," warns expert Dr. Susan Jebb. That rate of regain suggests a return to pre-treatment weight in about 18 months. Analyzing Approaches The analysis, which looked at dozens of trials involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with conventional dieting. The team point out that individuals who shed pounds through dieting typically have a less rapid creep back—around 100 grams monthly—post-intervention. Understanding the Quick Regain Experts believe the mode of action of the injections explains the accelerated regain. GLP-1 drugs imitate a natural hormone called GLP-1, which moderates hunger. "Sustained high doses of GLP-1 levels far above than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert. "Withdrawal of this GLP-1 'fix' results in appetite is uncontrolled, making binge eating much more probable." An Ongoing Disease? The NHS suggest the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications. A number of clinicians say that, due to the high risk of weight regain, the treatment should be considered ongoing. This perspective is supported by drug manufacturers, who note that the results "highlight the persistent character of excess weight," comparing it to managing diseases like hypertension. User Testimonies Users who have discontinued the medication explain a intense resurgence of appetite. "It was like something activating and you're instantly ravenous," described one woman. The struggle is exacerbated if users have not developed permanent dietary or behavioural modifications during therapy. Widespread Use Survey data suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow. Adoption is higher among women than males. The middle-aged age group shows the greatest usage rates. A large proportion access the medications through private healthcare rather than the NHS. Ultimately, researchers stress that while these medications are potent agents for weight loss, they are not a magic fix and long-term success hinges on ongoing lifestyle support.
Obesity treatment involves ongoing approaches. A recent study suggests that individuals who come off new weight-loss injections like Wegovy and Mounjaro can put back on shed pounds much more quickly than those who end conventional lifestyle regimens. Research printed in a leading medical journal points out that while overweight individuals can lose about a fifth of their body weight while using the jabs, the weight comes back at an average rate of nearly a kilo each month once they quit. "People purchasing these treatments must be informed of the danger of fast rebound weight gain when the treatment ends," warns expert Dr. Susan Jebb. That rate of regain suggests a return to pre-treatment weight in about 18 months. Analyzing Approaches The analysis, which looked at dozens of trials involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with conventional dieting. The team point out that individuals who shed pounds through dieting typically have a less rapid creep back—around 100 grams monthly—post-intervention. Understanding the Quick Regain Experts believe the mode of action of the injections explains the accelerated regain. GLP-1 drugs imitate a natural hormone called GLP-1, which moderates hunger. "Sustained high doses of GLP-1 levels far above than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert. "Withdrawal of this GLP-1 'fix' results in appetite is uncontrolled, making binge eating much more probable." An Ongoing Disease? The NHS suggest the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications. A number of clinicians say that, due to the high risk of weight regain, the treatment should be considered ongoing. This perspective is supported by drug manufacturers, who note that the results "highlight the persistent character of excess weight," comparing it to managing diseases like hypertension. User Testimonies Users who have discontinued the medication explain a intense resurgence of appetite. "It was like something activating and you're instantly ravenous," described one woman. The struggle is exacerbated if users have not developed permanent dietary or behavioural modifications during therapy. Widespread Use Survey data suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow. Adoption is higher among women than males. The middle-aged age group shows the greatest usage rates. A large proportion access the medications through private healthcare rather than the NHS. Ultimately, researchers stress that while these medications are potent agents for weight loss, they are not a magic fix and long-term success hinges on ongoing lifestyle support.